These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 16688294)

  • 1. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study].
    Codina C; Miró JM; Tuset M; Claramonte J; Gomar C; Gotsens R; Gómez B; Suárez S; Abellana R; Ascaso C; Cartaña R; Rodríguez E; Asenjo M; Carné X; Trilla A; Marco F; Gómez J; Brunet M; Pomar JL; Gatell JM; Ribas J
    Med Clin (Barc); 2000; 114 Suppl 3():54-61. PubMed ID: 10994565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
    Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
    Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
    Wilcox M; Nathwani D; Dryden M
    J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.
    Laohavaleeson S; Barriere SL; Nicolau DP; Kuti JL
    Pharmacotherapy; 2008 Dec; 28(12):1471-82. PubMed ID: 19025428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment of gram-positive infections: focus on efficacy, safety, and cost minimalization analysis of teicoplanin.
    Crane VS; Garabedian-Ruffalo SM
    Hosp Formul; 1992 Dec; 27(12):1199-200, 1203-4, 1207-10. PubMed ID: 10122506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
    Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital.
    Sancar AA; Yegenoglu S; de Vries R; Postma MJ; Simsek N; Pechlivanoglou P; Unal S
    Pharm World Sci; 2008 Dec; 30(6):916-23. PubMed ID: 18803030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of Gram-negative resistance.
    Evans HL; Lefrak SN; Lyman J; Smith RL; Chong TW; McElearney ST; Schulman AR; Hughes MG; Raymond DP; Pruett TL; Sawyer RG
    Crit Care Med; 2007 Jan; 35(1):89-95. PubMed ID: 17110877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teicoplanin vs vancomycin: cost-effectiveness comparisons.
    Rybak MJ
    Hosp Formul; 1993 Jan; 28 Suppl 1():28-32. PubMed ID: 10123835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic model to evaluate antibiotic costs.
    Garrelts JC; Horst WD; Silkey B; Gagnon S
    Pharmacotherapy; 1994; 14(4):438-45. PubMed ID: 7937280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
    D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
    Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
    Davis SL; McKinnon PS; Hall LM; Delgado G; Rose W; Wilson RF; Rybak MJ
    Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients.
    Abad F; Calbo F; Zapater P; Rodríguez-Vilanova F; García-Pérez L; Sacristán JA
    Int J Antimicrob Agents; 2000 Jun; 15(1):65-71. PubMed ID: 10856679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.
    Spencer CM; Bryson HM
    Pharmacoeconomics; 1995 Apr; 7(4):357-74. PubMed ID: 10155323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacoeconomic assessment of daptomycin as first-line therapy for bacteraemia and complicated skin and skin structure infections caused by gram-positive pathogens in Spain].
    Grau S; Rebollo P; Cuervo J; Gil-Parrado S
    Rev Esp Quimioter; 2011 Sep; 24(3):154-63. PubMed ID: 21947099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
    López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
    Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus.
    Menzin J; Marton JP; Meyers JL; Carson RT; Rothermel CD; Friedman M
    Am J Infect Control; 2010 Feb; 38(1):44-9. PubMed ID: 19762120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.